We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Alnylam Grants Bio-Rad License to Kreutzer-Limmer Patents for the RNAi Research Products Market
News

Alnylam Grants Bio-Rad License to Kreutzer-Limmer Patents for the RNAi Research Products Market

Alnylam Grants Bio-Rad License to Kreutzer-Limmer Patents for the RNAi Research Products Market
News

Alnylam Grants Bio-Rad License to Kreutzer-Limmer Patents for the RNAi Research Products Market

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Alnylam Grants Bio-Rad License to Kreutzer-Limmer Patents for the RNAi Research Products Market "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Alnylam Pharmaceuticals, Inc. has granted Bio-Rad a non-exclusive license to provide RNAi research products under the Kreutzer-Limmer patent family.

This patent family, owned exclusively by Alnylam, covers small interfering RNAs (siRNAs) and their use to mediate RNAi in mammalian cells.

“Execution of this license agreement with Bio-Rad, a global leader in the life science research community, continues to underscore the value of the Kreutzer-Limmer patent family as a critical component of fundamental intellectual property in the field of RNAi,” said Roland Kreutzer, Ph.D., Managing Director of Alnylam Europe AG.

“This agreement brings the number of licenses that Alnylam has granted to more than 20, including 13 with research product suppliers. In fact, we believe that over 75 percent of industrial sales of siRNAs for research purposes are currently being made under access to Alnylam’s intellectual property.”

Alnylam’s intellectual property estate includes certain fundamental patents and patent applications that claim the broad structural and functional properties of synthetic RNAi products. These include the Kreutzer-Limmer I and II patents, acquired through the 2003 merger of Alnylam with Ribopharma.

Advertisement